Article info
Clinical and epidemiological research
Extended report
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- Correspondence to Dr G J Wolbink, Department of Rheumatology, Jan van Breemen Institute, Dr Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands; g.wolbink{at}janvanbreemen.nl
Citation
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
Publication history
- Accepted August 10, 2010
- First published November 10, 2010.
Online issue publication
January 13, 2011
Article Versions
- Previous version (10 November 2010).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions